Conclusion of COP16 Negotiations on Multilateral Mechanism for Benefit-Sharing of DSI
On the conclusion of the COP16 negotiations on proposals to include digital sequence information (DSI) within the scope of the Convention of Biodiversity (CBD), IFPMA Director General, Dr. David Reddy, said:
“The pharmaceutical industry has long supported the Convention on Biological Diversity’s objective to protect our natural world and will continue to engage in discussions on mechanisms that safeguard biodiversity while fostering scientific research and innovation”.
“The decision adopted today does not get the balance right between the intended benefits of such a mechanism and the significant costs to society and science that it has the potential to create”.
“The ability to rapidly use scientific data known as “digital sequence information” (DSI) is essential for developing new medicines and vaccines. Any new system should not introduce further conditions on how scientists access such data and add to a complex web of regulation, taxation and other obligations for the whole R&D ecosystem – including on academia and biotech companies. New technologies that use DSI can contribute to conservation and sustainable use of biodiversity and should be encouraged”.
“Ahead of COP17, it is critical that governments work to ensure the implementation of any new mechanism on digital sequence information does not stifle the medical research and innovation that can bring the next wave of medical progress to people around the world.”
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
